What to do when your grant application fails
All hope should not be lost and an unsuccessful application doesn’t always mark the end of the road.
Post-hype, pre-value: The real AI-pharma shift starts now
The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.
UK project addresses capacity issue in CGT manufacturing
A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Takeda's narcolepsy programme gets back on track
Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
5th Oligonucleotides for CNS Summit
The Oligonucleotides for CNS Summit returns for its 5th year to address key challenges in durability, scalability, potency and CNS tropism
Immune Cell Engager Partnering & Investment Summit
Driving high ROI across immune cell engagers through strategic partnerships & investments, capitalizing on novel targets & asset tunability...
2nd ADC & Novel Conjugates Partnering & Investment Summit
Refine your strategy, sharpen your positioning, and meet the right partners - all at the most efficient networking event of the ADCconference calendar
2nd Autoimmunity & Inflammation Partnering & Investment Summ...
Driving deal-making across targeted cell depletion, checkpoint agonism, tolerance, and oral anti-inflammatory biologics...
Welcome to the 2nd Raw Materials for Cell & Gene Therapy Sum...
Streamline Supply Chain Communications to Optimize Phase Appropriate QC Testing, Comparability & GMP Manufacturing of Raw Materials...